Headache recurrence and treatment

被引：3
作者：
Sheena K. Aurora
John Dempsey
机构：
[1] Swedish Headache Center,Swedish Neuroscience Institute
来源：
Current Treatment Options in Neurology | 2002年 / 4卷 / 5期
关键词：
Migraine; Sumatriptan; Migraine Attack; Main Drug Interaction; Zolmitriptan;
D O I：
10.1007/s11940-002-0043-z
中图分类号：
学科分类号：
摘要：
The definition of recurrence includes the following: any headache occurring after a headache-free state at 2 hours and within 24 hours after intake of drug; a headache that has never been studied systematically; a headache that may not be an outcome of drug treatment; a headache that may be due to the inherent nature of migraine and individual patient characteristics such as duration of attack; and headache for which effective treatment may be a re-dose of the initial medication or addition of steroidal or nonsteroidal anti-inflammatory medications.
引用
收藏
页码：335 / 342
页数：7
相关论文
共 104 条
[1]  
Ferrari M(1999)How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence Cephalalgia 19 2-8
[2]  
Goldstein DJ(1999)Efficacy definitions for migraine studies Cephalalgia 19 248-249
[3]  
Offen WW(1997)A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan [abstract] Cephalalgia 17 426-426
[4]  
Moster MB(1998)Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan Headache 38 184-190
[5]  
Göbel H(1995)High efficacy and low frequency of headache recurrence after oral sumatriptan J Int Med Res 23 96-105
[6]  
Boswell D(1995)Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan Neurology 45 1505-1509
[7]  
Winter P(1996)Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice Q J Med 89 613-622
[8]  
Crisp A(1998)Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicenter, dose-range finding study Eur J Neurol 5 535-543
[9]  
Pfaffenrath V(1997)Optimizing the dose of zolmitriptan for the acute treatment of migraine: a multicenter, double blind, placebo-controlled, dose range-finding study Neurology 49 1210-1218
[10]  
Cunin G(1997)Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine: the 042 Clinical Trial Study Group Neurology 49 1219-1225
12345678910